Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

Gilead Sciences and Second Genome Signs a Four-Year Collaboration to Identify Biomarkers and Therapies Targeting Inflammatory Bowel Disease

Shots:

  • Second Genome will receive $38M as upfront, up to $300M milestones for each of five target discovery programs and royalties for approved therapies. Additionally, it will receive milestones for each validated biomarker delivered under the collaboration
  • The collaboration will deploy Second Genome’s Microbiome Analytics Platform to identify biomarkers associated with clinical response in up to 5 of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases and to identify up to 5 novel therapies targeting IBD over the next 4yrs., with an option to extend the collaboration for an additional 2yrs.
  • Gilead to get the global option rights for up to 5 programs targeting all diseases along with exclusive rights to all biomarkers developed under the collaboration

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Second Genome